Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation

Journal of Neuroimmunology

Volumn 282, Issue , 2015, Pages 118-122

  Berger, Benjamin ^a   Baumgartner, Annette ^a   Rauer, Sebastian ^a   Mader, Irina ^a   Luetzen, Niklas ^a   Farenkopf, Ulrich ^b   Stich, Oliver ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Medical Practice   (Germany)

Author keywords

Cessation; Fingolimod; Multiple sclerosis; Reactivation; Rebound

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CONTRAST ENHANCEMENT; CRANIAL NEUROPATHY; DETERIORATION; DISEASE ACTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; GAIT DISORDER; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PARESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; SUBARACHNOID HEMORRHAGE; VERTIGO; VISUAL IMPAIRMENT; YOUNG ADULT; ANALOGS AND DERIVATIVES; DISABILITY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADULT; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; YOUNG ADULT;

EID: 84928545069     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.03.022     Document Type: Article

References (22)

1. Baumgartner A., Stich O., Rauer S. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab. Int. J. Neurosci. 2012, 122:35-39.
2. Boriello G., Prosperini L., Mancinelli C., Gianni C., Fubelli F. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur. J. Neurol. 2012, 19:783-787.
3. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., Pelletier J., Capra R., Gallo P., Izquierdo G., Tiel-Wilck K., de Vera A., Jin J., Stites T., Wu S., Aradhye S., Kappos L., TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:402-415.
4. De Vera A., Kappos L., Zhang-Auberson L., Tang D., Cohen J.A. Pooled efficacy data demonstrate that fingolimod reduces multiple sclerosis relapse rate with no evidence of rebound after discontinuing treatment. Abstract book. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 13-16 October 2010, Gothenburg, Sweden 2010.
5. Fox R.J., Cree B.A., De Sèze J., Gold R., Hartung H.P., Jeffery D., Kappos L., Kaufman M., Montalbán X., Weinstock-Guttman B., Anderson B., Natarajan A., Ticho B., Duda P. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014, 82:1491-1498.
6. Ghezzi A., Rocca M.A., Baroncini D., Annovazzi P., Zaffaroni M., Minonzio G., Comi G., Filippi M. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. J. Neurol. 2013, 260:327-329.
7. Gross C.M., Baumgartner A., Rauer S., Stich O. Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 2012, 79:2006-2007.
8. Hakiki B., Portaccio E., Giannini M., Razzolini L., Pastò L., Amato M.P. Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. Mult. Scler. 2012, 18:1636-1639.
9. Havla J.B., Pellkofer H.L., Meinl I., Gerdes L.A., Hohlfeld R., Kümpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch. Neurol. 2012, 69:262-264.
10. http://www.kompetenznetz-multiplesklerose.de/images/stories/PDF_Dateien/Leitlinie/dgn-kknms_ms-ll_kap5.5.1-fty720_20140813.pdf.
11. Johnson T.A., Shames I., Keezer M., Lapierre Y., Haegert D.G., Bar-Or A., Antel J. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin. Immunol. 2010, 137:15-20.
12. Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P., Selmaj K., Agoropoulou C., Leyk M., Zhang-Auberson L., Burtin P., FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387-401.
13. Kaufman M., Cree B.A., De Sèze J., Fox R.J., Gold R., Hartung H.P., Jeffery D., Kappos L., Montalbán X., Weinstock-Guttman B., Ticho B., Duda P., Pace A., Campagnolo D. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J. Neurol. 2015, 262:326-336.
14. La Mantia L., Prone V., Marazzi M.R., Erminio C., Protti A. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia. Neurol. Sci. 2014, 35:1485-1486.
15. Martinelli V., Colombo B., Dalla Costa G., Dalla Libera D., Moiola L., Falini A., Comi G., Filippi M. Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Mult. Scler. 2013, 10.1177/1352458513492246.
16. Mehling M., Kappos L., Derfuss T. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. Curr. Neurol. Neurosci. Rep. 2011, 11:492-497.
17. Miravalle A., Jensen R., Kinkel R.P. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch. Neurol. 2011, 68:186-191.
18. Piscolla E., Hakiki B., Pastò L., Razzolini L., Portaccio E., Amato M.P. Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient. J. Neurol. 2013, 260:1675-1677.
19. Sempere A.P., Berenguer-Ruiz L., Feliu-Rey E. Rebound of disease activity during pregnancy after withdrawal of fingolimod. Eur. J. Neurol. 2013, 20:109-110.
20. Vollmer T., Radue E.W., Vermersch P., von Rosenstiel P., Putzki N., Meinel M., Sfikas N., Merschhemke M., Freedman M.S. Clinical and magnetic resonance imaging disease activity after fingolimod discontinuation. Abstract book. 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2-5 October 2013, Copenhagen, Denmark 2013, 548. (October).
21. West T.W., Killestein J., Fox R.J. Natalizumab discontinuation: an increasingly tricky proposition. Eur. J. Neurol. 2012, 19:663-664.
22. Willis M.A., Cohen J.A. Fingolimod therapy for multiple sclerosis. Semin. Neurol. 2013, 33:37-44.